Basilea is currently conducting pivotal randomized Phase III studies focusing on first-line treatment against invasive aspergillus or candida bloodstream infections. This additional supportive international multicenter safety and efficacy study will include aspergillosis patients with impaired renal function and patients with rare mold infections.
The study is expected to provide additional confirmation of the potential advantages of intravenous and oral isavuconazole over existing antifungals in terms of consistently effective drug levels, convenience, and clinical safety. These data are intended to complement the planned regulatory package.